WO2005054426A3 - Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof - Google Patents

Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof Download PDF

Info

Publication number
WO2005054426A3
WO2005054426A3 PCT/SE2004/001814 SE2004001814W WO2005054426A3 WO 2005054426 A3 WO2005054426 A3 WO 2005054426A3 SE 2004001814 W SE2004001814 W SE 2004001814W WO 2005054426 A3 WO2005054426 A3 WO 2005054426A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
angiogenesis
compositions
proteins
relates
Prior art date
Application number
PCT/SE2004/001814
Other languages
French (fr)
Other versions
WO2005054426A2 (en
Inventor
Mats Hellstroem
Elisabet Wallgard
Mattias Kalen
Original Assignee
Angiogenetics Sweden Ab
Mats Hellstroem
Elisabet Wallgard
Mattias Kalen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0303268A external-priority patent/SE0303268D0/en
Application filed by Angiogenetics Sweden Ab, Mats Hellstroem, Elisabet Wallgard, Mattias Kalen filed Critical Angiogenetics Sweden Ab
Priority to NZ547877A priority Critical patent/NZ547877A/en
Priority to CA002548208A priority patent/CA2548208A1/en
Priority to JP2006542541A priority patent/JP2007512835A/en
Priority to EP04801722A priority patent/EP1699818A2/en
Priority to US10/581,761 priority patent/US20090036362A1/en
Priority to AU2004295654A priority patent/AU2004295654A1/en
Publication of WO2005054426A2 publication Critical patent/WO2005054426A2/en
Publication of WO2005054426A3 publication Critical patent/WO2005054426A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/05Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/40Fish
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • A01K2267/0375Animal model for cardiovascular diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.

Abstract

The present invention relates to polynucleotides and proteins associated with vasculogenesis- and angiogenesis-related disorders. The invention further relates to methods for the identification of compounds that modulate the expression of angiogenesis-related genes and gene products and to using such compounds as therapeutic agents in the treatment of angiogenesis-related disorders. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of angiogenesis-related disorders, and to methods and compositions for the treatment these disorders.
PCT/SE2004/001814 2003-12-05 2004-12-06 Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof WO2005054426A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
NZ547877A NZ547877A (en) 2003-12-05 2004-12-06 Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof
CA002548208A CA2548208A1 (en) 2003-12-05 2004-12-06 Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof
JP2006542541A JP2007512835A (en) 2003-12-05 2004-12-06 Polypeptides, proteins and compositions affecting angiogenesis and methods of using the same
EP04801722A EP1699818A2 (en) 2003-12-05 2004-12-06 Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use
US10/581,761 US20090036362A1 (en) 2003-12-05 2004-12-06 Angiogenesis Affecting Polypeptides, Proteins, and Composition, and Methods of Use Thereof
AU2004295654A AU2004295654A1 (en) 2003-12-05 2004-12-06 Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48174103P 2003-12-05 2003-12-05
SE0303268A SE0303268D0 (en) 2003-12-05 2003-12-05 Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof
SE0303268-7 2003-12-05
US60/481,741 2003-12-05

Publications (2)

Publication Number Publication Date
WO2005054426A2 WO2005054426A2 (en) 2005-06-16
WO2005054426A3 true WO2005054426A3 (en) 2005-08-04

Family

ID=34656372

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2004/001814 WO2005054426A2 (en) 2003-12-05 2004-12-06 Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof

Country Status (6)

Country Link
EP (1) EP1699818A2 (en)
JP (1) JP2007512835A (en)
AU (1) AU2004295654A1 (en)
CA (1) CA2548208A1 (en)
NZ (2) NZ577564A (en)
WO (1) WO2005054426A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2042514A1 (en) * 2007-09-25 2009-04-01 Life & Brain GmbH Maintenance of hair growth and treatment of hair-loss
PL3485903T3 (en) 2011-09-23 2023-06-12 Mereo Biopharma 5, Inc. Vegf/dll4 binding agents and uses thereof
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1114862A2 (en) * 1999-11-17 2001-07-11 Switch Biotech Aktiengesellschaft Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in indentifying pharmacologically acitve substances
WO2003026403A2 (en) * 2001-09-24 2003-04-03 Deltagen, Inc. Ctsz disruptions, compositions and methods relating thereto
US20030100497A1 (en) * 2001-06-20 2003-05-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2003046578A2 (en) * 2001-11-29 2003-06-05 Novartis Ag Method for the assessment and prognosis of sarcoidosis
WO2003072827A1 (en) * 2001-10-31 2003-09-04 Children's Hospital Medical Center Method for diagnosis and treatment of rheumatoid arthritis
EP1347059A1 (en) * 2002-03-20 2003-09-24 Biofrontera Pharmaceuticals AG Cathepsin Y for the development of a medicament for the treatment of stroke
WO2003079982A2 (en) * 2002-03-19 2003-10-02 Tularik Inc. Gene amplification in cancer
WO2004030615A2 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1114862A2 (en) * 1999-11-17 2001-07-11 Switch Biotech Aktiengesellschaft Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in indentifying pharmacologically acitve substances
US20030100497A1 (en) * 2001-06-20 2003-05-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2003026403A2 (en) * 2001-09-24 2003-04-03 Deltagen, Inc. Ctsz disruptions, compositions and methods relating thereto
WO2003072827A1 (en) * 2001-10-31 2003-09-04 Children's Hospital Medical Center Method for diagnosis and treatment of rheumatoid arthritis
WO2003046578A2 (en) * 2001-11-29 2003-06-05 Novartis Ag Method for the assessment and prognosis of sarcoidosis
WO2003079982A2 (en) * 2002-03-19 2003-10-02 Tularik Inc. Gene amplification in cancer
EP1347059A1 (en) * 2002-03-20 2003-09-24 Biofrontera Pharmaceuticals AG Cathepsin Y for the development of a medicament for the treatment of stroke
WO2004030615A2 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1491, 2000, pages 93 - 106 *
BOHLING F. ET AL.: "Cathepsins K, L, B, X and W are differentially expressed in normal and chronically inflamed gastric mucosa", BIOL. CHEM., vol. 385, May 2004 (2004-05-01), pages 439 - 445 *
DATABASE EMBL [online] DEUSSING J. ET AL.: "Murine and human cathepsin Z: cDNA-cloning, characterization of the genes and chromosomal localization", Database accession no. (AF136273) *
DATABASE EPOP [online] Database accession no. (AX140435) *
DATABASE GENESEQ [online] Database accession no. (ABM82268) *
DATABASE GENESEQ [online] Database accession no. (ADD49940) *
DATABASE GENESEQ [online] Database accession no. (ADP65017) *

Also Published As

Publication number Publication date
WO2005054426A2 (en) 2005-06-16
NZ547877A (en) 2009-07-31
AU2004295654A1 (en) 2005-06-16
CA2548208A1 (en) 2005-06-16
NZ577564A (en) 2010-04-30
EP1699818A2 (en) 2006-09-13
JP2007512835A (en) 2007-05-24

Similar Documents

Publication Publication Date Title
WO2004076639A3 (en) Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
ATE269402T1 (en) IKK-BETA PROTEINS, NUCLEIC ACIDS AND METHODS
WO1999058675A3 (en) Human genes and gene expression products v
MX344216B (en) Genetic products differentially expressed in tumors and the use thereof.
WO2002014500A3 (en) Human genes and gene expression products
WO1999038972A3 (en) Human genes and gene expression products ii
DK1641818T3 (en) Polypeptides that have binding affinity for HER2
WO2001066753A3 (en) Human genes and gene expression products
WO2002088750A3 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2001064877A3 (en) Human schizophrenia gene
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
DE69826493D1 (en) IKK-ALPHA PROTEINS, NUCLEIC ACIDS AND METHOD
WO2005026205A3 (en) Genetic products which are differentially expressed in tumours and use thereof
MXPA05011085A (en) Compositions and methods relating to stop-1.
WO1999051186A3 (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
WO2004066933A3 (en) Compositions and methods for treating cancer using igsf9 and liv-1
EP1197550A3 (en) Methods and compositions for diagnosing and treating disorders involving angiogenesis
WO2005054426A3 (en) Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof
WO2001020026A3 (en) POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
WO2005019259A3 (en) Variants of interleukin-1 receptor antagonist: compositions and uses thereof
MXPA03010728A (en) B7 related protein-2 molecules and uses thereof.
WO2005017161A3 (en) Chimeric peptides for the regulation of gtpases
SE0303268D0 (en) Angiogenesis affecting polypeptides, proteins, and compositions, and methods of use thereof
WO2000018916A3 (en) Human genes and gene expression products
WO2001072781A3 (en) Human genes and expression products

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2548208

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006542541

Country of ref document: JP

Ref document number: 2004295654

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004801722

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 547877

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 3720/DELNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004295654

Country of ref document: AU

Date of ref document: 20041206

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004295654

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200480040284.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2004801722

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10581761

Country of ref document: US